The new site will use new technologies to enhance the efficiency and capability to produce a wide range of medicines in Amgen’s pipeline
Amgen Thousand Oaks campus. (Credit: Amgen Inc.)
US-based biopharmaceutical company Amgen has started construction on its new biomanufacturing facility, located in Holly Springs, North Carolina, US.
The new production facility is expected to address the rising demand for the company’s therapies for chronic conditions such as cancer and heart disease.
Integrated Project Services has been contracted to lead the construction management and design services for the new facility, which is expected to be operational by 2025.
Amgen said that the new site will use new technologies to enhance the efficiency and capability to produce a wide range of medicines in its pipeline.
In addition, the facility will be constructed abiding by environmental standards and in line with the company’s water usage, waste management and carbon neutrality goals for 2027.
Amgen chairman and CEO Robert Bradway said: “For over four decades, Amgen has been an innovative leader in the manufacturing of complex biologics.
“Our commitment to continuous improvement and our significant investments in new technologies have enabled us to further accomplish our mission to serve patients while science rapidly evolves.
“We are delighted to be building our newest facility in North Carolina, a major hub for biopharmaceutical innovation.”
Amgen said that it has selected North Carolina based on access to a diverse workforce in the region.
North Carolina Governor Roy Cooper said: “Amgen is adding to North Carolina’s strong economic growth with the addition of its newest manufacturing plant to our already robust biomanufacturing ecosystem.
“We welcome Amgen’s choice to build a state-of-the-art facility in our world-renowned Research Triangle region, bringing more than 350 high-quality new jobs to our state.”
In November last year, Amgen started construction on its new biomanufacturing plant located in New Albany, Ohio, US, with an investment worth $365m.
The new facility, which is expected to start operations by 2024, will be used to assemble the final product and packaging of medicines that address the growing demand in the US.